About
Allero Therapeutics develops non-invasive, antigen-specific immunotherapies using its proprietary SOMIT platform to induce long-lasting immune tolerance for autoimmune and allergic diseases as well as to prevent anti-drug antibodies.
Explore Allero Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.